Categories: News

Soleno Therapeutics Announces Presentations at ENDO 2022

REDWOOD CITY, Calif., June 07, 2022 (GLOBE NEWSWIRE) — Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced presentations at the upcoming ENDO 2022, which is being held June 11-14, 2022, in Atlanta, Georgia, USA.

Details of the presentations are as follows:

2022 Endocrine Society Meeting (ENDO)

Title: Hormonal and Cardiometabolic Changes Associated with Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
Format: Oral Presentation
Presenter: Dr. Eric Felner on behalf of the DESTINY PWS Investigators and Soleno Therapeutics
Date: Sunday, June 12, 2022
Time: 11 AM to 12:30 PM Eastern Time

Title: Long-Term Safety of Diazoxide Choline Extended-Release (DCCR) Tablets in Patients with Prader-Willi Syndrome
Format: Poster
Presenter: Dr. Michael Woloschak on behalf of the DESTINY PWS Investigators and Soleno Therapeutics
Date: Sunday, June 12, 2022
Time: 1:00 PM ET

The copy of the presentation materials will be available in the Investors section on the Company’s website at www.soleno.life after presentation at the meeting.

About Soleno Therapeutics, Inc.
Soleno is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. The company’s lead candidate, DCCR, a once-daily oral tablet for the treatment of Prader-Willi syndrome (PWS), is currently being evaluated in an ongoing Phase 3 clinical development program. For more information, please visit www.soleno.life.

Corporate Contact:
Brian Ritchie
LifeSci Advisors, LLC
212-915-2578

Staff

Recent Posts

What Is the Best GLP-1 Supplement for Weight Loss? Industry Analysis Reveals Probiotic Akkermansia Formulas as Affordable Ozempic Alternatives

Health Journey Addresses 'Best GLP-1 Supplement' Question with Akkermansia-Based Formula Analysis as Six-Month Costs Compare…

13 hours ago

After Trump’s Marijuana Executive Order, Will the DEA Face a Court Imposed Deadline from MMJ’s Writ of Mandamus?

After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…

1 day ago

Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings

Boards and executive buyers are raising the 2026 bar for all product and service rankings…

1 day ago

Black Book Research Releases Its 2026 Annual Methodology and Governance Statement for Healthcare IT Vendor Rankings

Boards and executive buyers are raising the 2026 bar for all product and service rankings…

1 day ago

Awake Breast Augmentation: Gruber Plastic Surgery Highlights Live Implant Sizing Under Local Anesthesia With No Sedation for Eligible Patients

Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…

2 days ago